Regulus Therapeutics Inc RGLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RGLS is a good fit for your portfolio.
News
-
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
-
Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew?
-
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
-
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Trading Information
- Previous Close Price
- $2.69
- Day Range
- $2.64–2.83
- 52-Week Range
- $1.08–3.79
- Bid/Ask
- $2.40 / $2.91
- Market Cap
- $173.48 Mil
- Volume/Avg
- 406,153 / 3.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 30
- Website
- https://www.regulusrx.com
Valuation
Metric
|
RGLS
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
RGLS
|
---|---|
Quick Ratio | 2.79 |
Current Ratio | 3.31 |
Interest Coverage | −51.50 |
Quick Ratio
RGLS
Profitability
Metric
|
RGLS
|
---|---|
Return on Assets (Normalized) | −71.03% |
Return on Equity (Normalized) | −97.08% |
Return on Invested Capital (Normalized) | −86.87% |
Return on Assets
RGLS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bryhrznml | Gkym | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dnyhfqxf | Mgdqgv | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Klfnqxh | Bmrngx | $103.7 Bil | |
MRNA
| Moderna Inc | Fdcvkhxs | Ldfpn | $47.9 Bil | |
ARGX
| argenx SE ADR | Wlxkrjhd | Jbmp | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Cyqmvccp | Vmvcs | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zdnbkvp | Gwbskxx | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pcwkckkr | Wwqckk | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wjlghbkh | Tkfxh | $12.8 Bil | |
INCY
| Incyte Corp | Ngpnlfv | Srhjgf | $12.1 Bil |